Are you Idumi Mochimatsu?

Claim your profile

Publications (2)3.56 Total impact

  • Article: Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.
    [show abstract] [hide abstract]
    ABSTRACT: Regression of tumor mass by chemotherapy is caused by growth suppression and/or apoptosis of tumor cells. Therefore, expression levels of cell cycle molecules and apoptosis should be predictive markers for the efficacy of a drug. In the present study, the relationship between expression of molecules in the cell cycle and apoptosis and chemosensitivity was investigated in head and neck squamous cell carcinoma cell lines. Expression of p53, p21, p27, cyclin D1, cyclin E, and Bax in 17 such cell lines were analyzed by Western blot analysis. The concentrations of four chemotherapeutic agents (cisplatin, 5-FU, vincristine, and paclitaxel) resulting in 50% cell growth inhibition were calculated as IC50 values for each cell line. Cell cycle analysis was performed using a FACScan flow cytometer. Cells with strong expression of p21, p27, or Bax showed significantly higher sensitivity to cisplatin, and cells with strong expression of Bax or weak expression of cyclin E showed significantly higher sensitivity to paclitaxel. Cisplatin most effectively killed cells expressing both p21 and p27 or either at G1 phase. Though the assessments of p21, p27, Bax, and cyclin E expression in tumor tissues have been reported to be useful as prognostic factors in head and neck squamous cell carcinoma, these correlations might not only describe the malignant biological behavior of the tumor, but also the response to chemotherapy. Furthermore, p21/p27 expression might be a useful guide for the choice of chemotherapeutic agents.
    Oncology Reports 03/2004; 11(2):421-6. · 1.84 Impact Factor
  • Article: Combined radiotherapy and chemotherapy with carboplatin and UFT for head and neck squamous cell carcinoma.
    [show abstract] [hide abstract]
    ABSTRACT: The purpose of this study was to evaluate the toxicity and to determine adequate doses of combined concurrent therapy with carboplatin/UFT and radiotherapy. This regimen was designed for use on patients with complications of renal dysfunction, ischemic heart disease, or advanced age. Twenty-seven eligible patients with stages II-IV squamous cell carcinomas of the head and neck were treated with concurrent chemoradiotherapy. UFT was given orally at a dose of 300 mg/day daily. Carboplatin was given intravenously once a week at a dose of AUC 3-6. Radiotherapy was delivered in single daily fractions of 1.8-2.0 Gy, to a total dose of 66-70.2 Gy. Unacceptable toxicity (neutropenic fever or mucotitis) was encountered with a carboplatin dose of AUC 6 and a UFT dose of 300 mg/day. Combined radiotherapy and chemotherapy with carboplatin and UFT is a safe and well-tolerated regimen.
    Anticancer research 23(1B):713-7. · 1.73 Impact Factor